Illumina (NASDAQ:ILMN) CAO Sells $225,150.00 in Stock

by · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) CAO Scott Ericksen sold 1,500 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

Shares of NASDAQ:ILMN traded up $1.44 during trading on Monday, reaching $164.40. 2,190,365 shares of the company traded hands, compared to its average volume of 1,870,274. The company’s 50 day moving average is $133.73 and its two-hundred day moving average is $132.09. The firm has a market capitalization of $24.87 billion, a PE ratio of 29.89, a PEG ratio of 2.70 and a beta of 1.50. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 52 week low of $78.79 and a 52 week high of $165.97.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business earned $0.97 earnings per share. Illumina’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ILMN. Barclays upped their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Canaccord Genuity Group decreased their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Evercore restated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Finally, Weiss Ratings downgraded Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $138.38.

View Our Latest Stock Report on Illumina

Hedge Funds Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares during the period. HighPoint Advisor Group LLC increased its holdings in Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares during the period. Meeder Advisory Services Inc. raised its position in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the last quarter. Toronto Dominion Bank raised its position in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after buying an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Read More